Author

Vijai Simha

Institutions: Indian Cancer Society, Sri Shankara Cancer Hospital and Research Center

Observed institutions: Indian Cancer Society, Sri Shankara Cancer Hospital and Research Center

ORCID: 0000-0001-5632-5275

Observed ORCID: 0000-0001-5632-5275

OpenAlex ID: A5137177341

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial

2026 · R. Dent, Z. Shao, et al. · Annals of Oncology · 48

Targeting HER-2 pathway in presence of cardiac dysfunction: the walk on a tight rope

2026 · Vijai Simha, Bhargav Raj, et al. · Clinical Cancer Bulletin

Scaling prior authorization for philanthropic funding with artificial intelligence (AI): Five-year outcomes from Indian Cancer Society Cancer Cure Fund (ICS-CCF) NavyaAI implementation.

2026 · Nehal Rishi Khanna, Vijai Simha, et al. · Journal of Clinical Oncology

Works count: 3

Citation count: 48

H-index: 1

I10-index: 1